The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
HRQoL was evaluated among RBC-TD patients with lower-risk non-del(5q) MDS treated with lenalidomide (n = 160) or placebo (n = 79) in the phase 3 MDS-005 study. Lenalidomide did not worsen HRQoL; response to lenalidomide was associated with significant HRQoL improvement. Lenalidomide represents a treatment option for patients with lower-risk non-del(5q) MDS who are ineligible for or refractory to ESAs.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Rena Buckstein, C.L. Beach, Shien Guo, Arman Altincatal, Chengqing Wu, Pierre Fenaux Source Type: research